Skip to main content
SpringerLink
Log in

HER-2/neu genotype of breast cancer may change in bone metastasis

  • Article
  • Published:
Pathology & Oncology Research

Abstract

The genotype of breast cancer (BRC) is considered to be relatively stable during tumor progression, accordingly, determination of the estrogen receptor and HER-2/neu status is currently based on the primary tumor. However, recent data suggest that the gene expression profile of the metastatic lesion can be different compared to that of the primary BRC. Accordingly, it is possible that the HER-2/neu status is different in the metastatic lesion and the primary BRC. Since the bone is the most frequent metastatic site during the progression of BRC, we have analyzed the HER-2/neu status of 48 bone metastatic BRC cases by immunohistochemistry and fluorescent in situ hybridization, and it was possible to compare it to the primary site in 23 cases. The frequency of HER-2/neu amplification of BRC in the primary tumors was found to be 17.4% compared to 10.5% in bone metastases. Half of BRC cases with HER-2/neu amplification lost this genotype in bone metastases (4/23 versus 2/23, respectively) and even in the 2 cases where HER-2/neu amplification was retained in the metastases, the copy number was found to be decreased compared to the primary tumor. Based on our data and previous reports in the literature, we suggest to perform HER-2/neu testing both on primary tumor and samples obtained from BRC metastases, at least in case of primary tumors with HER-2/neu amplification, before introduction of HER-2/neu-targeting therapy. (Pathology Oncology Research Vol 12, No 3, 149–152)

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Mendelsohn J, Baselga J: The EGF receptor family as targets for cancer therapy. Oncogene 19: 6550–6565, 2000

    Article  PubMed  CAS  Google Scholar 

  2. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177–182, 1987

    Article  PubMed  CAS  Google Scholar 

  3. Yu D, Hung MC: Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene 19: 6115–6121, 2000

    Article  PubMed  CAS  Google Scholar 

  4. Tsuda H, Hirohashi S, Shimotaso Y, et al: Correlation between long term survival in breast cancer patients and amplification of two putative oncogene co-amplification units: hst-1/int-2 and c-erbB-2/ear-1. Cancer Res 49:3104–3108, 1989

    PubMed  CAS  Google Scholar 

  5. de Bono JS, Rowinsky EK: The ErbB receptor family: a therapeutic target for cancer. Trends Mol Med 8 (4 suppl): S19-S26, 2002

    Article  PubMed  Google Scholar 

  6. Ross JS, Fletcher JA: HER-2/neu (c-erb-B2) gene and protein in breast cancer. Am J Clin Pathol 112: 53–67, 1999

    Google Scholar 

  7. Cobleigh MA, Vogel CL, Triphaty D et al: Multinational study of the efficacy and safety of humanized anti-HER-2/NEU monoclonal antibody in woman who have HER-2/NEU-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17: 2639–2648, 1999

    PubMed  CAS  Google Scholar 

  8. Smith IE: Efficacy and safety of Herceptin®in women with metastatic breast cancer: Result from pivotal clinical studies. Anticancer Drugs 12(suppl4):S3-S10, 2001

    PubMed  Google Scholar 

  9. Di Leo A, Dowsett M, Horten B, et al: Current status of HER-2/neu testing. Oncology 63(suppl 1): 25–32, 2002

    Article  PubMed  CAS  Google Scholar 

  10. Gancberg M, Di Leo A, Rouas G et al: Comparison of topoisomerase IIα (topoIIα) and HER-2 status between primary (P) breast cancer (BC) and corresponding metastatic (M) sites. Ann Oncol 13: 1036–1043, 2002

    Article  PubMed  CAS  Google Scholar 

  11. Fidler IJ: Review: biologic heterogeneity of cancer metastasis. Breast Cancer Res Treat 9:17–26, 1987

    Article  PubMed  CAS  Google Scholar 

  12. Masood S, Bui MM: Assessment of Her-2/neu overexpression in primary breast cancers and their metastatic lesions: an immunohistochemical study. Ann Clin Lab Sci 30: 259–265, 2000

    PubMed  CAS  Google Scholar 

  13. Shimizu C, Fukutomi T, Tsuda H et al: c-erbB-2 protein overexpression and p53 immunoreaction in primary and recurrent breast cancer tissues. J Surg Oncol 73: 17–20, 2000

    Article  PubMed  CAS  Google Scholar 

  14. Carlsson J, Nordgren H, Sjöström J et al: HER-2/NEU expression in breast cancer primary tumours and corresponding metastases. Original data and literature review. Br J Cancer 90: 2344–2348, 2004

    PubMed  CAS  Google Scholar 

  15. Vincent-Salomon A, Jouve M, Genin P et al: HER-2/NEU status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process. Cancer 94: 2169–2173, 2002

    Article  PubMed  CAS  Google Scholar 

  16. Tanner M, Järvinen P, Isola J: Amplification of Her-2/neu and topoisomerase IIα in primary and metastatic breast cancer. Cancer Res 61:5345–5348, 2001

    PubMed  CAS  Google Scholar 

  17. Kunitomo K, Inoue S, Ichihara F et al: A case of metastatic breast cancer with outgrowth of HER-2/NEU-negative cells after eradication of HER-2/NEU-positive cells by humanized anti-HER-2/NEU monoclonal antibody (trastuzumab) combined with docetaxel. Hum Pathol 35:379–381, 2004

    Article  PubMed  Google Scholar 

  18. Zidan J, Dashkovsky I, Stayerman C et al: Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br J Cancer 93: 552–556, 2005

    Article  PubMed  CAS  Google Scholar 

  19. Latinovic L, Heinze G, Birner P et al: Prognostic relevance of three histological grading methods in breast cancer. Int J Oncol 19: 1271–1277, 2001

    PubMed  CAS  Google Scholar 

  20. Press MF, Slamon DJ, Flom KJ et al: Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol 20: 3095–3105, 2002

    PubMed  CAS  Google Scholar 

  21. Bruun Rasmussen B, Kamby C: Immunohistochemical detection of oestrogen receptors in paraffin sections from primary and metastatic breast cancer. Pathol Res Pract 185:856–859, 1989

    Google Scholar 

  22. Woelfle U, Cloos J et al: Molecular signature associated with bone marrow micrometastasis in human breast cancer. Cancer Res 63:5679–5684, 2003

    PubMed  CAS  Google Scholar 

  23. Yoneda T: Cellular and molecular mechanism of breast and prostate can cer metastasis to bone. Eur J Cancer 34: 240–245, 1998

    Article  PubMed  CAS  Google Scholar 

  24. Gong Y, Booser DJ, Sneige N: Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma. Cancer 103: 1763–1769, 2005

    Article  PubMed  CAS  Google Scholar 

  25. Regitnig P, Schippinger W, Lindbauer M et al. Change of HER-2/neu status in a subset of distant metastases from breast carcinomas. J Pathol 203: 918–926, 2004

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Orthopedics, Semmelweis University, Budapest, Hungary

    Tamás Lőrincz, Gayane Badalian & Miklós Szendrői

  2. Department of Human and Experimental Pathology, National Institute of Oncology, Budapest, Hungary

    József Tóth

  3. Department of Tumor Progression, National Institute of Oncology, Budapest, Hungary

    József Tímár MD, PhD, DSc

Authors
  1. Tamás Lőrincz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. József Tóth
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gayane Badalian
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. József Tímár MD, PhD, DSc
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Miklós Szendrői
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to József Tímár MD, PhD, DSc.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lőrincz, T., Tóth, J., Badalian, G. et al. HER-2/neu genotype of breast cancer may change in bone metastasis. Pathol. Oncol. Res. 12, 149–152 (2006). https://doi.org/10.1007/BF02893361

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02893361

Key words

Search

Navigation